Longeveron
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Longeveron sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Longeveron: 7 sponsored US clinical trials, none currently recruiting.
Longeveron sponsors 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hypoplastic Left Heart Syndrome, with 1 trials.
Upper-quartile sponsor footprint
Longeveron sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
7 total, page 1 of 1
Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.
NCT04925024
Lomecel-B Effects on Alzheimer's Disease
NCT05233774
Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty
NCT03169231
Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty
NCT02982915
Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease
NCT02600130
Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome
NCT02398604
AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery
NCT02065245
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 3 |
Therapeutic Areas
How the Longeveron early-phase archive is shaped
7 indexed studies, none listed as recruiting (0% open); 5 completed (71%).
Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).
Top condition: Hypoplastic Left Heart Syndrome (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Longeveron: archived-pipeline peers nationwide
Peers matched on 7 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Longeveron sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 archived trials
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Longeveron page
7 registered trials is a research-attention snapshot, not an endorsement of Longeveron or any single study.
- None of Longeveron's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Hypoplastic Left Heart Syndrome is the condition Longeveron studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hypoplastic Left Heart Syndrome trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Longeveron pipeline card: 7 registered trials from official public datasets.Report a data error.